Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2025 Earnings Call Transcript March 12, 2026 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.17, expectations were $-0.22551.

I’ll browse platforms like X, Substack and YouTube, selecting the most provocative articles and video clips to present the following morning. It’s a testament to how quickly artificial intelligence’s ...

More than 15,000 students — including six in 10 children and youth in one Manitoba school division — were chronically absent ...

His marriage is being dramatized in 'Love Story.' But there was a time when JFK Jr. lived in Providence, right on Benefit ...

The first two new EVs will be called Cosmos and Earth, and Lucid wants to help Tesla owners 'upgrade' from Models S and X.

Good afternoon, everyone, and welcome to SentinelOne's earnings call for the fiscal year ended January 31, 2026. With us today are Tomer Weingarten, CEO; and Barry Padgett, Interim CFO.

After years on SSRIs, one man shares what it’s like to live with genital numbness, delayed orgasm, and a changed sex life.

Ooops... Something went wrong while loading this page.

BriteCo reports lab-grown diamonds now cost 73% less than natural ones, capturing over 45% of US engagement ring sales, ...

The Museum of Worcester's new exhibition "Worcester to the Stars" opens March 16. The exhibition celebrates Robert H. Goddard ...

It’s writing a travel story about Ireland for a Boston newspaper. Boston has the largest Irish population of any major US ...

Plummeting literacy rates have fueled a bitter debate over how best to teach reading. And artificial intelligence turning up ...